Clinical trial · no report yet · Phase 2
NCT04585477
Adjuvant ctDNA-Adapted Personalized Treatment in Early Stage NSCLC (ADAPT-E)
- NCT04585477 ↗
- Suspended
- Stanford University
- Focused
We haven't built a report for this trial yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Preliminary discovery
Commentary in our index that names this trial so far
Podcasts, YouTube videos and X posts we have indexed. A report screens them, searches for more and cites what clinicians said when it is built, so final coverage is set at build.
| Channel | Found | |
|---|---|---|
| X threads | 4 |
The trial
ClinicalTrials.gov- Official title
- Adjuvant ctDNA-Adapted Personalized Treatment in Early Stage NSCLC (ADAPT-E)
- Phase
- Phase 2
- Status
- Suspended
- Conditions
- Non-small Cell Lung Cancer; Non-small Cell Lung Cancer Stage I; Non-small Cell Lung Cancer Stage II; Non-small Cell Lung Cancer Stage III
- Interventions
- AVENIO ctDNA Surveillance Kit; Durvalumab; Durvalumab (Imfinzi) alone or in combination with platinum-based chemotherapy
- Arms
- Cohort 1 minimal residue disease positive(MRD+) · Experimental
- Cohort 2 minimal residue disease negative (MRD-) · Active comparator
- Enrollment
- 80 (estimated)
- Primary outcomes
- Decrease in ctDNA Level
- Sponsor
- Stanford University with AstraZeneca
- Start
- Apr 8, 2021
- Primary completion
- Dec 30, 2026 (estimated)
- Results posted
- No
- Registry record
- NCT04585477 · updated Jul 7, 2026